News for Vaccinex, Inc. (VCNX)

Vaccinex (VCNX) announces promising clinical data for pepinemab in head and neck cancer. Pepinemab shows enhanced immune response and improved pathologi

Pepinemab enhances immunotherapy effectiveness, inducing tumor immunity in challenging cancer cases. Key clinical trials demonstrate pepinemab's capabil

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in pat

Vaccinex (VCNX) announces delisting from Nasdaq, with trading suspended since Dec 18, 2024. Learn about their next steps and Form 25 plans.

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX) (

Transaction Overview On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a significant transaction involving Vaccinex Inc (VCNX). The firm

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.61%

U.S. stocks traded lower midway through trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded down 0.59% to 43,459.99 while the NASDAQ fell ...

Following breaching minimal listing criteria, Vaccinex (VCNX, Financials) will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial

Vaccinex stock plunges to 52-week low at $1.36 amid market challenges

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded d...

Vaccinex (VCNX) faces delisting from Nasdaq due to failure to meet listing standards.

Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex

**media[459115]**

**media[452903,452904]**

The rising incidence of Alzheimer's and other tau-related disorders, driven by an aging global population, is significantly boosting the demand for...

The growing demand for corporate wellness is largely driven by factors such as increased screen time, higher workloads, rapid urbanization, poor diet,...

The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET)..

The surge in neuroendoscopy demand is chiefly fueled by the increasing occurrence of neurological conditions like brain tumors. Furthermore, the escalating...